ReviewNature reviews. Cancer2017
Engineering and physical sciences in oncology: challenges and opportunities.
Review in Nature reviews. Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 98 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Artificial intelligence in cytopathological applications for cancer: a review of accuracy and analytic validity.European journal of medical research · 2024Pooled it
- 'Nano Scale [is] Magic Scale': On EPR, Unicorns, and Enchantment in Nanomedicine.Social studies of science · 2026Article
- Quantitative oncogene-mapping within malignant tumors through Multi-parameter MRI based on RNA-triggered nanoprobes.Materials today. Bio · 2026Article
- Ferroptosis: The dawn of reversing drug resistance in digestive cancers.Genes & diseases · 2026Review
- Redox-Programmed Activation of a Dual-Modal Probe for High-Fidelity Tumor Delineation and Image-Guided Surgery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cancer cell-dependent increase in senescence-like populations following exosome treatment: The role of extracellular matrix and cellular glycocalyx.World journal of stem cells · 2026Article
- Cancer-Associated Adipocytes in Human Breast Cancer: An Observational Histopathological Study of Dedifferentiation and Stromal Transition.The breast journal · 2026Observational
- Integrated bioinformatics and deep learning (MLP) approach reveals a novel five miRNA prognostic signature in uveal melanoma.Scientific reports · 2025Article
- Nanoparticle-Based Delivery Strategies for Combating Drug Resistance in Cancer Therapeutics.Cancers · 2025Review
- Targeting phosphatidylserine in tumor cell membranes with a zinc-containing molecule to efficiently combat tumor metastasis.Journal of nanobiotechnology · 2025Article
- Using mathematical modelling and AI to improve delivery and efficacy of therapies in cancer.Nature reviews. Cancer · 2025Review
- A data-efficient strategy for building high-performing medical foundation models.Nature biomedical engineering · 2025Article
- Losartan as a mechanotherapeutic adjuvant: Remodeling the breast tumor microenvironment to improve treatment efficacy.PloS one · 2025Article
- Triphenylphosphine-Based Mitochondrial Targeting Nanocarriers: Advancing Cancer Therapy.Clinical pharmacology : advances and applications · 2025Review
- A photo-controlled charge regulator improves cancer theranostics.Nature nanotechnology · 2024Article
- Physiochemically and Genetically Engineered Bacteria: Instructive Design Principles and Diverse Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Side-view optical microscopy-assisted atomic force microscopy for thickness-dependent nanobiomechanics.Nanoscale advances · 2024Article
- NIR-II light in clinical oncology: opportunities and challenges.Nature reviews. Clinical oncology · 2024Review
- Interstitial flow potentiates TGF-β/Smad-signaling activity in lung cancer spheroids in a 3D-microfluidic chip.Lab on a chip · 2024Article
- Human Intestinal Organoids and Microphysiological Systems for Modeling Radiotoxicity and Assessing Radioprotective Agents.Cancers · 2023Review
38 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
Abstract
The principles of engineering and physics have been applied to oncology for nearly 50 years. Engineers and physical scientists have made contributions to all aspects of cancer biology, from quantitative understanding of tumour growth and progression to improved detection and treatment of cancer. Many early efforts focused on experimental and computational modelling of drug distribution, cell cycle kinetics and tumour growth dynamics. In the past decade, we have witnessed exponential growth at the interface of engineering, physics and oncology that has been fuelled by advances in fields including materials science, microfabrication, nanomedicine, microfluidics, imaging, and catalysed by new programmes at the National Institutes of Health (NIH), including the National Institute of Biomedical Imaging and Bioengineering (NIBIB), Physical Sciences in Oncology, and the National Cancer Institute (NCI) Alliance for Nanotechnology. Here, we review the advances made at the interface of engineering and physical sciences and oncology in four important areas: the physical microenvironment of the tumour and technological advances in drug delivery; cellular and molecular imaging; and microfluidics and microfabrication. We discussthe research advances, opportunities and challenges for integrating engineering and physical sciences with oncology to develop new methods to study, detect and treat cancer, and we also describe the future outlook for these emerging areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.